DelveInsight’s, “Advanced Kidney Cancer Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape. It covers the Advanced Kidney Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Kidney Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Advanced Kidney Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Advanced Kidney Cancer Pipeline Outlook
Key Takeaways from the Advanced Kidney Cancer Pipeline Report
- On 17 August 2025, M.D. Anderson Cancer Center announced a Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma. Primary Objectives To determine the efficacy of objective response rate (ORR) and 24-week disease control rate (DCR), per RECIST 1.1, of ivonescimab monotherapy in participants with locally advanced or metastatic renal cell carcinoma with a clear cell component who had progression on at least one prior line of therapy.
- On 15 August 2025, Hoffmann-La Roche conducted a study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
- DelveInsight’s Advanced Kidney Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Advanced Kidney Cancer treatment.
- The leading Advanced Kidney Cancer Companies such as Corcept Therapeutics, Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune and others.
- Promising Advanced Kidney Cancer Pipeline Therapies such as TQB2450, Sunitinib, Anlotinib, epothilone b, HB0025, Ipilimumab, RAD001, Belzutifan, Famitinib, L19IL2, Bevacizumab and others.
Stay ahead with the most recent pipeline outlook for Advanced Kidney Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Advanced Kidney Cancer Treatment Drugs
Advanced Kidney Cancer Emerging Drugs Profile
- Savolitinib: AstraZeneca
Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification. The drug is currently being evaluated under Phase III clinical trial for the treatment of advanced kidney cancer.
- Relatlimab: Bristol-Myers Squibb
Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody and is expressed in a recombinant CHO cell line. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with advanced kidney cancer.
- JANX008: Janux Therapeutics
JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). The drug is currently being evaluated under Phase I clinical trial for the treatment of Advanced Kidney Cancer.
The Advanced Kidney Cancer Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Kidney Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Kidney Cancer Treatment.
- Advanced Kidney Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Advanced Kidney Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Kidney Cancer market
Explore groundbreaking therapies and clinical trials in the Advanced Kidney Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Advanced Kidney Cancer Drugs
Advanced Kidney Cancer Companies
Corcept Therapeutics, Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune and others.
Advanced Kidney Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Advanced Kidney Cancer Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Unveil the future of Advanced Kidney Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Advanced Kidney Cancer Market Drivers and Barriers
Scope of the Advanced Kidney Cancer Pipeline Report
- Coverage- Global
- Advanced Kidney Cancer Companies- Corcept Therapeutics, Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune and others.
- Advanced Kidney Cancer Pipeline Therapies- TQB2450, Sunitinib, Anlotinib, epothilone b, HB0025, Ipilimumab, RAD001, Belzutifan, Famitinib, L19IL2, Bevacizumab and others.
- Advanced Kidney Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Advanced Kidney Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Advanced Kidney Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Advanced Kidney Cancer Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Advanced Kidney Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced Kidney Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Savolitinib: AstraZeneca
- Mid Stage Products (Phase II)
- Relatlimab: Bristol-Myers Squibb
- Early Stage Products (Phase I)
- JANX008: Janux Therapeutics
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Advanced Kidney Cancer Key Companies
- Advanced Kidney Cancer Key Products
- Advanced Kidney Cancer- Unmet Needs
- Advanced Kidney Cancer- Market Drivers and Barriers
- Advanced Kidney Cancer- Future Perspectives and Conclusion
- Advanced Kidney Cancer Analyst Views
- Advanced Kidney Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-kidney-cancer-pipeline-insight